- Home
- CTMX vs PRLD Comparison
CTMX vs PRLD Comparison
Compare CTMX & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- PRLD
- Stock Information
- Founded
- CTMX 2008
- PRLD 2016
- Country
- CTMX United States
- PRLD United States
- Employees
- CTMX N/A
- PRLD N/A
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- CTMX Health Care
- PRLD Health Care
- Exchange
- CTMX Nasdaq
- PRLD Nasdaq
- Market Cap
- CTMX 62.3M
- PRLD 73.7M
- IPO Year
- CTMX 2015
- PRLD 2020
- Fundamental
- Price
- CTMX $0.59
- PRLD $0.71
- Analyst Decision
- CTMX Buy
- PRLD Strong Buy
- Analyst Count
- CTMX 6
- PRLD 2
- Target Price
- CTMX $5.77
- PRLD $4.50
- AVG Volume (30 Days)
- CTMX 3.5M
- PRLD 164.8K
- Earning Date
- CTMX 03-06-2025
- PRLD 03-10-2025
- Dividend Yield
- CTMX N/A
- PRLD N/A
- EPS Growth
- CTMX N/A
- PRLD N/A
- EPS
- CTMX 0.38
- PRLD N/A
- Revenue
- CTMX $138,103,000.00
- PRLD $7,000,000.00
- Revenue This Year
- CTMX N/A
- PRLD N/A
- Revenue Next Year
- CTMX N/A
- PRLD N/A
- P/E Ratio
- CTMX $1.55
- PRLD N/A
- Revenue Growth
- CTMX 36.45
- PRLD N/A
- 52 Week Low
- CTMX $0.56
- PRLD $0.66
- 52 Week High
- CTMX $5.85
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- CTMX 30.34
- PRLD 37.54
- Support Level
- CTMX $0.60
- PRLD $0.66
- Resistance Level
- CTMX $0.78
- PRLD $0.86
- Average True Range (ATR)
- CTMX 0.06
- PRLD 0.08
- MACD
- CTMX -0.00
- PRLD 0.00
- Stochastic Oscillator
- CTMX 13.69
- PRLD 18.76
Stock Price Comparison Chart: CTMX vs PRLD
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.